Estuardo Aguilar-Cordova Sells 1,800 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $6.85, for a total value of $12,330.00. Following the transaction, the insider now owns 959,873 shares in the company, valued at approximately $6,575,130.05. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Candel Therapeutics Stock Down 0.9 %

Shares of CADL opened at $6.65 on Friday. Candel Therapeutics, Inc. has a 52-week low of $0.66 and a 52-week high of $14.30. The company has a quick ratio of 1.62, a current ratio of 1.62 and a debt-to-equity ratio of 1.66. The stock has a fifty day simple moving average of $6.25 and a two-hundred day simple moving average of $6.48. The company has a market capitalization of $197.88 million, a PE ratio of -5.19 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Candel Therapeutics, Inc. will post -0.91 EPS for the current year.

Institutional Trading of Candel Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CADL. Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics during the 2nd quarter worth about $338,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Candel Therapeutics during the second quarter valued at about $162,000. Rhumbline Advisers purchased a new stake in shares of Candel Therapeutics in the 2nd quarter valued at approximately $143,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Candel Therapeutics in the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.